Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis

Effect of Co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs Placebo on Death, Lung Transplant, or Hospital Admission in Patients With Moderate and Severe Idiopathic Pulmonary Fibrosis

(2020) Andrew M. Wilson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Lung Microbiota Contribute to Pulmonary Inflammation and Disease Progression in Pulmonary Fibrosis

(2019) David N O'Dwyer et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Radiographic Honeycombing and Altered Lung Microbiota in Patients with Idiopathic Pulmonary Fibrosis

(2019) Robert P. Dickson et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Resistome analyses of sputum from COPD and healthy subjects reveals bacterial load-related prevalence of target genes

(2019) Mohammadali Yavari Ramsheh et al.   THORAX

Clinical Trials in Idiopathic Pulmonary Fibrosis in the “Posttreatment Era”

(2018) Kevin F. Gibson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The Potential Impact of Azithromycin in Idiopathic Pulmonary Fibrosis

(2018) Claudio Macaluso et al.   EUROPEAN RESPIRATORY JOURNAL

Randomised, double-blind, placebo-controlled trial with azithromycin selects for anti-inflammatory microbial metabolites in the emphysematous lung

(2016) Leopoldo N Segal et al.   THORAX

The Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet)

(2015) Joao de Andrade et al.   CHEST

A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials

(2015) Harold R. Collard et al.   EUROPEAN RESPIRATORY JOURNAL

Streptococcus pneumoniae triggers progression of pulmonary fibrosis through pneumolysin

(2015) S. Knippenberg et al.   THORAX

The PRECIS-2 tool: designing trials that are fit for purpose

(2015) K. Loudon et al.   BMJ-British Medical Journal

The PRECIS-2 tool: designing trials that are fit for purpose

(2015) K. Loudon et al.   BMJ-British Medical Journal

The Role of Bacteria in the Pathogenesis and Progression of Idiopathic Pulmonary Fibrosis

(2014) Phillip L. Molyneaux et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Study Design Implications of Death and Hospitalization as End Points in Idiopathic Pulmonary Fibrosis

(2014) Harold R Collard et al.   CHEST

Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study

(2014) MeiLan K Han et al.   Lancet Respiratory Medicine

A Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis

(2013) Brett Ley et al.   ANNALS OF INTERNAL MEDICINE

Effect of Long-term, Low-Dose Erythromycin on Pulmonary Exacerbations Among Patients With Non–Cystic Fibrosis Bronchiectasis

(2013) David J. Serisier et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effect of Azithromycin Maintenance Treatment on Infectious Exacerbations Among Patients With Non–Cystic Fibrosis Bronchiectasis

(2013) Josje Altenburg et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial

(2012) Ludmila Shulgina et al.   THORAX

Considerations when prescribing trimethoprim-sulfamethoxazole

(2011) J. M.- W. Ho et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL